About Us
Ainnocence is a global biotech company that leads in generative AI for therapeutic discovery, leveraging industry-grade sequence-based proprietary technology and training data from over 16 years of expertise.
Costly high-throughput wet lab screening, expensive structure biology, and inaccurate 3D modeling processes.
A radical AI drug discovery system accelerating life-saving therapies with unprecedented speed, deep virtual throughput, and higher success rates.
Platform Evolution
A decade of innovation: Communication Dynamics (2015) → Platform Development (2021) → Foundation Models (2026)
Research
Peer-reviewed research spanning AI, drug discovery, and computational biology
Demonstrating the power of sequence-based AI for therapeutic antibody design with unprecedented speed and accuracy.
Three foundational papers spanning biomolecular systems, periodic table orbitals, and neural network architecture
Pan et al. — Mathematical foundation for all Ainnocence platforms
CarbonAI platform, ParaVS framework, antibody affinity maturation, and more
14+ additional peer-reviewed publications
Intellectual Property
20+ PCT patents protecting our AI drug discovery methodologies
Contact